Document is current
Any future updates will be listed below
-
Authors
Lopez, Chloé
Licaj, Idlir
Dumas, Agnès
Havas, Julie
Di Meglio, Antonio
Luis, Ines Vaz
Pistilli, Barbara
André, Fabrice
Martin, Anne-Laure
Delmas, Dominique
Jouannaud, Christelle
Kaderbhai, Courèche
Cherifi, François
Campone, Mario
Mouret-Reynier, Marie-Ange
Ruiz-de-Azua, Garazi https://orcid.org/0000-0002-7784-7571
Menvielle, Gwenn
-
Funding
Funding for this research was provided by:
Agence Nationale de la Recherche (n°ANR-10-COHO-0004)
Fondation ARC pour la Recherche sur le Cancer (PGA1 RF20170205420)
Institut National Du Cancer (SHS-E-SP 2022-138)
- License Information
-
More Information
Article History
Received: 23 October 2025
Accepted: 18 February 2026
First Online: 12 March 2026
Declarations
:
: IVL: Honoraria: AstraZeneca (Inst), Amgen (Inst), Pfizer (Inst), Novartis (Inst), Sandoz (Inst); Research Funding: Resilience (Inst), Travel: Novartis BP: Consulting fees: Astra Zeneca (institutional), Seagen (institutional), Gilead (institutional), Novartis (institutional), Lilly (institutional), MSD (institutional), Pierre Fabre (personal), Daiichi-Sankyo (institutional/personal); Research funding (to my institution): Astra Zeneca, Daiichi-Sankyo, Gilead, Seagen, MSD; Travel support: Astra Zeneca; Pierre Fabre; MSD; Daiichi-Sankyo; Pfizer. All funding and competing interests declared were either institutional or personal as specified and are not related to the work presented in this manuscript.
